ClinicalTrials.gg

Program

ENN0403

A development code. Also written as “ENN0403, low dose”, “ENN0403, high dose” and “ENN0403 capsules, low dose”.

Its studies are mostly in Macular Edema · Acute Kidney Injury, led by EnnovaBio.

Furthest: phase 2, since Sep 29, 20243 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
EnnovaBio31 open or runningphase 2since Sep 29, 2024Aug 9, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 9, 2022First study: phase 1 study in HealthyFirst studyNCT05506540 · 69 enrolled · Australia
  2. Sep 29, 2024Phase 2 study in Cardiac Surgery Associated - Acute Kidney InjuryNCT06632613 · 200 planned · China
  3. Nov 25, 2024Phase 2 study in Diabetic Macular Edema (DME)NCT06708260 · 60 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06708260Diabetic Macular Edema (DME) · China2CompletedAug 12, 202660
NCT06632613Cardiac Surgery Associated - Acute Kidney Injury · China2RecruitingFeb 2026200
NCT05506540Healthy · Australia1CompletedMay 16, 202269

How it is read

Names in the registry

  • “ENN0403, low dose”, 1 entry
  • “ENN0403, high dose”, 1 entry
  • “ENN0403 capsules, low dose”, 1 entry
  • “ENN0403 capsules, high dose”, 1 entry
  • “ENN0403 1mg”, 1 entry

Codes read as this program: ENN0403.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.